CAMBRIDGE, Mass. and WASHINGTON, July 11,
2024 /PRNewswire/ -- Tiba Biotech LLC, a Cambridge-based preclinical biopharmaceutical
company, announces its new partnership with the Biomedical Advanced
Research and Development Authority (BARDA), part of the
Administration for Strategic Preparedness and Response (ASPR) at
the U.S. Department of Health and Human Services (HHS), through
initiation of an EZ-BAA contract to develop groundbreaking
therapeutics against influenza.
The U.S. $749,999 contract,
awarded through a highly competitive review process, supports
early-stage therapeutic platform development for the Flexible and
Strategic Therapeutics (FASTx) program of BARDA. This initiative
aims to advance cutting-edge therapeutic platform technologies,
such as RNA-mediated interference (RNAi), which could be rapidly
deployed in response to emerging viral threats. Tiba Biotech's
initial focus will be on developing a prototype RNAi-based
therapeutic for H1N1 influenza that targets the highly conserved
viral nucleoprotein and will be delivered via Tiba's
RNABLTM platform.
"We are excited to receive this BARDA award, which will advance
Tiba's innovative approach to combating influenza and other viral
threats," said Dr. Jasdave Chahal, co-founder and lead investigator
of the project. "We believe our technology has the potential to
transform the landscape of RNA therapeutics." This initiative is a
natural extension of Tiba's ongoing work combating influenza
pandemic threats, most notably in the form of a novel multi-antigen
mRNA-based H7N9 flu vaccine funded under a Phase II SBIR award from
the National Institutes of Health (NIH) and ongoing collaborations
with the Collaborative Influenza Vaccine Innovation Centers
(CIVICs).
Tiba was also recently accepted into BLUE KNIGHT ™, a joint
initiative between Johnson & Johnson Innovation – JLABS
('JLABS') and BARDA, with an aim to harness innovation to combat
future known and unknown health threats.
This project is being supported in whole with federal funds from
the Department of Health and Human Services; Administration for
Strategic Preparedness and Response; Biomedical Advanced Research
and Development Authority (BARDA), under contract number
75A50124C00014.
About Tiba Biotech
Tiba Biotech is a preclinical stage biopharmaceutical company
developing next-generation RNA vaccines and therapeutics based on a
novel dendrimer nanoparticle delivery platform, initially developed
at the Massachusetts Institute of
Technology and the Whitehead Institute for Biomedical
Research. Tiba Biotech's nanoparticle delivery platform can safely
enable large vaccine and therapeutic payloads with relaxed
cold-chain requirements and superior safety compared to existing
RNA delivery technologies, providing protection against multiple
human and animal diseases. For more information about Tiba Biotech,
visit www.tiba.bio, follow us on X (formally Twitter) @TibaBiotech
and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/barda-partners-with-tiba-biotech-to-develop-innovative-therapeutics-against-influenza-302194714.html
SOURCE Tiba Biotech